<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000767621"><TermName>Gardasil 9</TermName><TermPronunciation>(GAR-duh-sil …)</TermPronunciation><TermDefinition><DefinitionText>A vaccine used to prevent anal, cervical, vulvar, and vaginal cancer caused by human papillomavirus (HPV) types 16, 18, 31, 33, 45, 52 and 58 and genital warts caused by HPV types 6 and 11. Gardasil 9 is approved for use in males aged 9 to 15 years and females aged 9 to 26 years. It is a type of nonavalent vaccine (a vaccine that works against nine different viruses or other microorganisms). Also called recombinant human papillomavirus nonavalent vaccine.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000769333" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Gardasil 9&quot;" language="en" id="_3"/><MediaLink ref="CDR0000769332" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Gardasil 9&quot;" language="es" id="_4"/><SpanishTermName>Gardasil 9</SpanishTermName><SpanishTermDefinition><DefinitionText>Vacuna que se usa para prevenir los cánceres anales, de cuello uterino, de vulva y de vagina causados por los tipos 16, 18, 31, 33, 45, 52 y 58 del virus del papiloma humano (VPH), así como las verrugas genitales causadas por los tipos 6 y 11 del VPH. El uso de Gardasil 6 está aprobado para varones de 9 a 15 años  y mujeres de 9 a 26 años. Es un tipo de vacuna nonavalente (una vacuna que es eficaz contra nueve virus diferentes u otros microorganismos). También se llama vacuna nonavalente recombinante contra el virus del papiloma humano.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2014-12-29</DateFirstPublished><RelatedInformation><RelatedDrugSummaryRef href="CDR0000767283">Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
